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Poster Session I 75Results: Patients have had a median of 10 to 124 ECP treat-
ments. The median number of treatments that enabled initial
ECP schedule taper was 22(10–124) and to achieve a CR was 62
treatments. Objective response was achieved 61% of patients (CR
in 2 patients at 8 and 15 months; PR in 6 patients). Fifteen percent
had stable disease and 23% progressed. At the time of this report 6
patients are still receiving ECP. Refer to table for organ-specific re-
sponse. Of note, six of 10 patients with lichenoid GVHD and 3 of 4
with sclerotic GVHD improved. Nine patients have been able to ta-
per corticosteroids$50% from starting dose. Five patients have
died (3 with progressive GVHD, 2 with infection/GVHD).
ECP is an alternative effective method to treat moderate to severe
SR cGVHD in pediatric patients. ECP has allowed for significant
corticosteroid sparing. Prospective studies are necessary to deter-
mine optimal schedule and durability of response.
Response by Organ
System Manifestation N CR PR SD PDSkin Rash/Lichenoid 10 2 4 4 -
Fasciitis/Scleroderma 4 1 2 1 -Oral Symptoms/
lichenoid/erythema9 2 7 - -Ocular Symptoms/need
for treatment3 1 1 1 -Joints Arthralgias/
Contractures5 2 1 2 -GI Vomiting/Abdominal
Pain/Diarrhea3 - 1 2 -Liver Bilirubin . 2 8 1 2 3 2
Pulmonary Worsening
symptoms/PFTs
4 - 1 2 1202
PRELIMINARY RESULTS OF A PHASE I STUDY OF IMMUNO-CHEMO-
THERAPY (CTX) CONDITIONING WITH GEMTUZUMAB OZOGAMICIN
(GO), BUSULFAN (Bu) AND CYCLOPHOSPHAMIDE (Cy) FOLLOWED BY
ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PEDIATRIC
RECIPIENTS WITH HIGH RISK (HR) CD331 ACUTE MYELOGENOUS
LEUKEMIA (AML)
Waxman, I., Bhatia, M., Qualter, E., Jin, Z.Z., Kohl, V., Baldinger, L.,
Guerra, J., Garvin, J., George, D., Bradley, M.B., Satwani, P.,
Schwartz, J., Baxter-Lowe, L.A., Wolonik, K., Foley, S., Hawks, R.,
Militano, O., van de Ven, C., Mitchell, C.S. 1Columbia University,
New York, NY; 2UCSF, San Francisco, CA.
Survival following AlloSCT for HR AML ($CR3, induction fail-
ure [IF], refractory disease) is dismal (#10%). BuCy is standard
conditioning in children with good risk AML (Woods et al, Blood,
2001). CD33 is expressed in 80–90% of childhood AML (Creutzig
et al, Blood, 1997). GO, an anti-CD33 immunotoxin, induces re-
mission in 20–30% of relapsed/refractory childhood AML (Arceci
et al, Blood, 2005). We have reported the safety of GO as post-con-
solidation therapy after reduced intensity conditioning alloSCT in
good risk childhood AML (Roman et al, Clin Can Res, 2005). In
this study, we explore the feasibility and safety of combination im-
muno-CTX conditioning with GO and myeloablative (MA) BuCy
followed by alloSCT in pediatric recipients with HR CD331
AML. Nine patients, median age 8 yr (0.75–17 yr) with HR
CD331 AML (1 CR3, 5 IF, 3 refractory disease) were studied. Do-
nor sources were: 1 6/6 HLA-matched sibling peripheral blood
stem cell (PBSC), 1 10/10 matched unrelated donor (MUD), 7 um-
bilical cord blood (UCB) (2 6/6, 2 5/6 and 3 4/6). Conditioning was
GO on day -14, Bu (12.8 mg/kg if age. 4 yr; 16 mg/kg if age\4 yr)
day -7 to -4 and Cy (120 mg/kg) day -3 to -2. Unrelated alloSCT
recipients received rabbit antithymocyte globulin (8 mg/kg) from
day -5 to -2. GO was given as a dose escalation; 3 patients each re-
ceived 3 mg/m2, 4.5 mg/m2 and 6 mg/m2. All patients received
enoxaparin (1 mg/kg) from day -15 to 121 as prophylaxis for sinu-
soidal obstruction syndrome (SOS). There has been no GO dose
limiting toxicity to date. Mean neutrophil and platelet engraftment
in all patients was on day 24 6 10 (n5 8) and day 546 49 (n5 7),respectively. In the UCB group, mean neutrophil and platelet en-
graftment was on day 28 6 8 (n 5 6) and day 64 6 56 (n 5 5), re-
spectively. Mean donor chimerism on days 30 and 60 was 96%65
and 96%610, respectively. One patient (GO dose 4.5 mg/m2) de-
veloped mild SOS on day 33 that resolved without therapy. One pa-
tient died of extensive chronic graft vs. host disease on day 269 and 4
of progressive disease (day. 200), while 4 are surviving recurrence-
free at a median of 52 months. Combination immuno-CTX condi-
tioning with GO and MA BuCy followed by AlloSCT has been well
tolerated to date in children with HR CD331 AML and resulted in
$95% donor chimerism. The maximal tolerated dose (MTD) of
GO as part of a preparative regimen for MA alloSCT in children
with CD331 AML has yet to be determined. We are currently ac-
cruing patients at the next dose level of GO (7.5 mg/m2).203
UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOR HE-
MOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
Staba Kelly, S.1, Shahlaee, A.1, Szabolcs, P.2, Driscoll, T.2, Eslin, D.3,
Kurtzberg, J.2, Martin, P.L.2. 1University of Florida, Gainesville, FL;
2Duke UniversityMedical Center, Durham,NC; 3M.D. Anderson Can-
cer Center Orlando, Orlando, FL.
Familial Hemophagocytic Lymphohistiocytosis (HLH) is a rare
disorder of immunoregulation that is usually fatal if untreated.
Characterized by fever, hepatosplenomagaly, CNS disease, coagu-
lation disorders, pancytopenia and hemaophagocytosis, onset is
usually prior to age 1. Stem cell transplant (SCT) is the only curative
option, however, most children lack suitable matched related do-
nors. Umbilical cord blood (UCB) is banked and rapidly available,
and it has a lower incidence of acute and chronic GVHD and less
viral contamination when compared with adult stem cell sources.
HLH is a disease of infants, so UCB cell dose is not a limiting factor.
All of these features make UCB an attractive stem cell source for
transplantation in this patient population, however there are few re-
ports of UCBT for HLH. Here we report the results of 10 children
treated at Duke University Medical Center and the University of
Florida with HLH who underwent unrelated donor UCBT be-
tween 1994 and 2007. Seven girls and 3 boys received their
UCBT at a median of 6 months of age, with all but one having
well controlled disease prior to transplant. Treatment prior to
UCBT was with VP-16, cyclosporine, and decadron. The prepara-
tive regimen consisted of busulfan (Bu), cyclophosphamide (Cy)/
Etoposide (VP-16)/antithymocyte globulin (ATG) in the 4 most re-
cent patients, and Bu/Cy/ATG in 6. All children successfully
achieved neutrophil engraftment at a median of 17 (range 13–26)
days. The median time to platelets greater than 50,000 was 53
days, and PRBC independence was 41 days. Four children experi-
enced grade I, 1 grade II, 1 grade III and 1 Grade IV acute
GVHD, while the remainder had none. All children with grade
II-IV GVHD received steroids and the child with grade IV
GVHD also received daclizumab. Other complications included
veno-occlusive disease (VOD) in 4 children, and infections. Eight
of 10 children (80%) are surviving event free for a median of 7 years
post transplant. One died at day1 30 of hepatic failure attributed to
VOD and GVHD, the other at day1 72 of pulmonary hemorrhage,
CMV and Parainfluenza pneumonia. Survival following SCT for
HLH is reported in many series at 50–60%. VOD, organ damage
and GVHD are significant contributors to morbidity and mortality.
In combination with initial HLH treatment, UCBT with a standard
myeloablative, chemotherapy-based preparative regimen appears
promising, providing an 80% event free survival in this pilot patient
population.204
CO-INFUSION OF MATCHED SIBLING DONOR CORD BLOOD AND BONE
MARROW AS STEM CELL SOURCE FOR ALLOGENEIC STEM CELL TRANS-
PLANTATION IN PEDIATRIC NON-MALIGNANT DISORDERS
Soni, S.1, Cowan, M.J.2, Edwards, S.3, Walters, M.C.3. 1Nationwide
Children’s Hospital, Columbus, OH; 2UCSF Children’s Hospital, San
Francisco, CA; 3Children’s Hospital and Research Center, Oakland, CA.
76 Poster Session IIntroduction: Cell dose is a critical factor influencing engraft-
ment and outcomes of cord blood (CB) transplantation. Rate of re-
jection is high (12–20%) in many pediatric non-malignant
disorders. Also, GVHD is not beneficial; 10–30% patients develop
acute GVHD $ grade II using bone marrow (BM) as the stem cell
source, while chronic GVHD occurs in 5–15% cases. During an
HLA-ID sibling donor (MSD)hematopoietic stem cell transplanta-
tion (HCT), the limited CB cell dose can be boosted by a BM har-
vest. We retrospectively studied the engraftment rate, incidence of
GVHD and outcomes of co-infusion of MSD CB and BM. Mate-
rials and Methods: 13 children underwent HCT after combining
CB and BM from their MSDs at multiple institutions between 6/
1998 to 6/2006. The data was collected from the Oakland Sibling
Cord Blood Registry database. Median age of patients was 5.9 years
(range: 2.2–13 yrs). HCT was performed for Thalassemia (n 5 7),
Sickle cell anemia (n 5 4), SAA and Hurler’s syndrome (1 each).
Most patients (9) received Busulfan, Cytoxan and ATG for condi-
tioning. The main reason for boosting CB with BM was a low
CD341 cell content in the CB unit. Median CB CD341 was 1.1
 105/kg (0.1–4.4  105/kg). The marrow cell dose ranged from
0.9  108/kg-2.6  108 TNC/kg recipient weight. Results: All 13
patients achieved donor engraftment. The median time to neutro-
phil recovery was 18 days (range: 12 to 27) and for platelet engraft-
ment was 29 days (range: 18 to 90). None of the patients developed
acute GVHD $ grade 2 and no chronic GVHD was reported.
There was no TRM and all patients remain alive with a median fol-
low-up of 1402 days (467–3406 days). None of the patients have re-
quired transfusions post-transplant and the patient with Hurler
syndrome has maintained 100% donor chimerism. Conclusions:
1. There were no engraftment failures after co-infusion compared
to the higher historical rates reported after HCT using BM or
CB alone in non-malignant conditions.
2. The addition of BM to boost the cellular content promoted rapid
engraftment. There was a more rapid rate of recovery of neutro-
phils and platelets particularly, compared to conventional CB
transplantation, which might have reduced TRM.
3. No acute or chronic GVHD was noted after co-infusion inspite
of increased cell dose. Combining CB to BM may have mitigated
the risk of GVHD.
4. Co-infusion of BM and CB is a feasible and effective strategy in
improving outcomes of HCT in non-malignant disorders, when
available in the MSD setting.Table 1. Patterns of chimerism
Chimerism
pattern N
% of donor
CD31 cells,
day 1 30
% of donor
cells in whole
blood, day 1 30
subsequent %
of donor
CD31 cells
subsequent %
of donor cells
in whole blood
Early complete
donor
chimerism (CDC)
2 $99 % $99% $99% $99%
CDC achieved later 4 26–91% 87–99% $99% by
7 months
post transplant
$99% by
7 months
post transplant
Increasing and
concordant
CD31 and WhBCh
5 .50% . 90% .80% by
7 months post
transplant
.90% by
7 months
post transplant
Low or fluctuating
CD31 chimerism,
stable WhBCh
8 8–77% 74–99% low or
.20% decline
with subsequent
gradual increase
to 45–95%
stable, 73–99%
Declining WhBCh,
low or fluctuating
CD31 chimerism,
discordant
CD31 and WhBCh
4 7–78% 79–99% low or
. 20% decline
with gradual
increase to
37–55%
decline over
time to 28–74%
Precipitous decline
in CD31 and WhBCh
2 63%; 1% 99%; 70% down to
0% by 2 months
post transplant
down to 0% and
13% by 2 months
post transplant205
LOW MOLECULAR WEIGHT HEPARIN (LMWH) PROPHYLAXIS (PPX) IN
PEDIATRIC RECIPIENTS FOLLOWING PEDIATRIC MYELOABLATIVE
STEM CELL TRANSPLANT (SCT) AT HIGH RISK FOR SINUSOIDAL OB-
STRUCTIVE SYNDROME (SOS): IS IT SAFE AND DOES IT MAKE A DIFFER-
ENCE?
Rogoza, K.1, Bhatia, M.2, Baldinger, L.1, van de Ven, C.2, Militano, O.1,
Qualter, E.1, Cairo, M.S.2. 1Morgan Stanley’s Children’s Hospital of
NewYork-Presbyterian, New York, NY; 2Columbia University, New
York, NY.
SOS is a clinical syndrome following SCT of jaundice, painful he-
patomegaly and weight gain with an incidence of 20% (2–54%) and
a mortality rate of 30–50%. The Children’s Group reported a 10%
incidence of SOS in pediatric recipients (n 5 2725; mild:3.1%,
moderate:5.2%, severe:2%) with a 1.8% mortality rate (Neider,
ASBMT, 2007). Risk factors include hepatitis, transaminitis, he-
patic irradiation, second SCT, and myeloablative conditioning reg-
imens (busulfan .8 mg/kg, cyclophosphamide $120 mg/kg, TBI,
and/or melphalan$135 mg/m2). We have demonstrated the safety
and efficacy of unfractionated heparin for SOS PPX in pediatric
SCT recipients (Rosenthal/Cairo et al, BMT, 1996). Simon et al
(BMT, 2001) demonstrated the use of LMWH for SOS PPX in
adult recipients. In this study we investigated the use of LMWH
in patients (pts) at high risk ($ 2 risk factors) for SOS to determine
if there was a difference in incidence of SOS compared with stan-
dard risk recipients not receiving LMWH. 36 pts at very high risk
for SOS received LMWH (1 mg/kg SQ) from 1st day of condition-
ing until D 1 21 post SCT. Median age 8.1 years (0.3–21, 23M/13F). Anti-Factor Xa levels were maintained between 0.3–0.5 Iu/
ml. Platelets were kept .30,000/mm3. Hemorrhage was graded
by NCI CTCAE 3.0. SOS was graded according to McDonald cri-
teria (Ann Int, 1993). 52 pts with\2 risk factors did not receive
LMWH PPX. Median age 8.6 years (0.3–23, 26M/26F). Of those
receiving LMWH, 4 pts developed SOS (mild, n 5 1; moderate,
n5 1; severe, n5 2). There were no hemorrhagic Grade III/IV tox-
icities. In the comparative standard risk group, 2 pts developed
moderate SOS. The probability of developing SOS in the high-
risk LMWH vs. comparison group was not significantly different:
11.1% (CI 95: 0.8–21.4) vs. 3.8%(CI95: 0–9.1), p 5 0.17 (Fig 1).
The OS in the LMWH group (50.3%) vs. the comparison standard
risk group (49.4%) was not statistically significant. No significant
difference in OS was observed in each sub-group who developed
SOS. These results suggest that LMWH can be administered safely
and may be effective SOS PPX in very high-risk pediatric SCT re-
cipients. A randomized double blind international trial comparing
LMWH vs. placebo will be required to determine the efficacy of
LMWH in pediatric SCT recipients at high risk of post SCT
SOS.206
FLUCTUATIONS IN CD31 SUBSET CHIMERISM ARE NOT PREDICTIVE OF
GRAFT REJECTION IN CHILDREN UNDERGOING TRANSPLANT FOR NON-
MALIGNANT DISORDERS
Ozyurek, E.1, Cowan, M.2, Koerper, M.2, Baxter-Lowe, L.A.3, Horn, B.2.
1Ondokuz University, Samsun, Turkey; 2University of California San
Francisco, San Francisco, CA; 3University of California San Francisco,
San Francisco, CA.
In non-malignant disorders, complete donor hematopoietic chi-
merism is not required for reversal or cure of underlying disease.
However, the risk of graft rejection may correlate with the degree
of donor chimerism. We postulated that the degree of donor chime-
rism, in particular, in CD31 cell lineage, may predict durability of
engraftment.
Retrospective chimerism data from 25 children undergoing 1st
transplant at UCSF between 2001 and 2007 were analyzed. The di-
agnoses included: bone marrow failure syndromes (N 5 9); meta-
bolic disorders (N 5 7); immunodeficiencies (N 5 6);
hemoglobinopathies (N 5 2); and autoimmune disorders (N 5 1).
